Your session is about to expire
← Back to Search
FWD1509 for Lung Cancer (FWD1509 Trial)
FWD1509 Trial Summary
This trial is testing a new cancer drug to see if it is safe and tolerated by patients with advanced lung cancer. They will also establish what the maximum tolerable dose is for this new drug.
FWD1509 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowFWD1509 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.FWD1509 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken strong CYP3A affecting drugs in the last 2 weeks.I haven't had cancer treatment in the last 21 days, or EGFR inhibitors in the last 7 days.I have spinal cord compression or cancer spread to the lining of my brain.I do not have any health conditions that could make the trial unsafe for me.My lung cancer is at an advanced stage (Stage IIIB/IIIC or IV).I have NSCLC and no other cancers, except for certain treated skin, cervical, or prostate cancers.I have serious heart problems that are not under control.I am currently pregnant, breastfeeding, or lactating.I am taking medications that affect how drugs are absorbed or processed by my body.I do not have severe heart, kidney, eye diseases, uncontrolled high blood pressure, lung conditions, or active infections.You must have at least one spot that can be measured and checked for changes according to specific guidelines.I have been treated with medication for my advanced or spread cancer.I am 18 years old or older.I have enough tumor tissue available for testing.I had radiotherapy less than 2 weeks ago or still have side effects.My organs are working well.I am willing and able to follow the study's schedule and procedures.I have brain metastases but meet certain conditions for treatment.I have not had major surgery in the last 4 weeks.I do not have stomach or bowel problems affecting medication absorption.I am fully active or restricted in physically strenuous activity but can do light work.You are expected to live for at least 3 more months.
- Group 1: Treatment of NSCLC patients with EGFR or HER2 genetic alterations
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are receiving therapy in this experiment?
"That is correct. The clinicaltrials.gov website states that the study is open for recruitment and lists 8/23/2021 as the date when the trial was first posted and 7/20/22 as the date of the most recent edit. Additionally, the site notes that 30 patients are needed at 2 locations."
Are we still admitting people into this research project?
"The answer is affirmative. The clinical trial in question, which was originally posted on 8/23/2021, as indicated by the data on clinicaltrials.gov, is currently recruiting patients. 30 participants are needed across 2 sites."
Share this study with friends
Copy Link
Messenger